118 related articles for article (PubMed ID: 27748052)
1. Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma.
Takada H; Tsuchiya K; Yasui Y; Nakakuki N; Tamaki N; Suzuki S; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Asahina Y; Enomoto N; Izumi N
Cancer Med; 2016 Nov; 5(11):3111-3120. PubMed ID: 27748052
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic performances of GALAD score in staging and 1-year mortality of hepatocellular carcinoma: A prospective study.
Jitpraphawan O; Ruamtawee W; Treewatchareekorn M; Sethasine S
World J Gastroenterol; 2024 May; 30(17):2343-2353. PubMed ID: 38813057
[TBL] [Abstract][Full Text] [Related]
3. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.
Norman JS; Li PJ; Kotwani P; Shui AM; Yao F; Mehta N
J Hepatol; 2023 Dec; 79(6):1469-1477. PubMed ID: 37683735
[TBL] [Abstract][Full Text] [Related]
4. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma.
Kumada T; Toyoda H; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tanaka J; Kagebayashi C; Satomura S
J Gastroenterol; 2014 Mar; 49(3):555-63. PubMed ID: 24057163
[TBL] [Abstract][Full Text] [Related]
5. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation.
Chaiteerakij R; Zhang X; Addissie BD; Mohamed EA; Harmsen WS; Theobald PJ; Peters BE; Balsanek JG; Ward MM; Giama NH; Moser CD; Oseini AM; Umeda N; Venkatesh S; Harnois DM; Charlton MR; Yamada H; Satomura S; Algeciras-Schimnich A; Snyder MR; Therneau TM; Roberts LR
Liver Transpl; 2015 May; 21(5):599-606. PubMed ID: 25789635
[TBL] [Abstract][Full Text] [Related]
6. The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data.
Li B; Liu A; Wen Y; Yang G; Zhao J; Li X; Mao Y; Li B
J Clin Lab Anal; 2021 Sep; 35(9):e23932. PubMed ID: 34403527
[TBL] [Abstract][Full Text] [Related]
7. GALAD score as a prognostic model for recurrence of hepatocellular carcinoma after local ablation.
Qiao W; Li J; Xiong Y; Zheng J; Jin R; Hu C
J Cancer Res Clin Oncol; 2024 May; 150(5):241. PubMed ID: 38713414
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Serum α-Fetoprotein Level as an Important Characteristic of Tumor Biology for Patients Undergoing Liver Resection of Early-Stage Hepatocellular Carcinoma (BCLC Stage 0/A): A Large Multicenter Analysis.
Yao LQ; Fan ZQ; Wang MD; Diao YK; Chen TH; Zeng YY; Chen Z; Wang XM; Zhou YH; Li J; Fan XP; Liang YJ; Li C; Shen F; Lv GY; Yang T
Ann Surg Oncol; 2024 Feb; 31(2):1219-1231. PubMed ID: 37925654
[TBL] [Abstract][Full Text] [Related]
9. Clinical features of patients with hepatocellular carcinoma treated with radiofrequency ablation therapy: developing a simple score to determine the need for immune-adjuvant therapy.
Tada F; Hiraoka A; Nakatani K; Matsuoka K; Fukumoto M; Matsuda T; Yanagihara E; Saneto H; Murakami T; Onishi K; Izumoto H; Kitahata S; Kanemitsu-Okada K; Kawamura T; Kuroda T; Hanaoka J; Watanabe J; Ohtani H; Yoshida O; Hirooka M; Miyata H; Tsubouchi E; Abe M; Matsuura B; Ninomiya T; Hiasa Y
Clin J Gastroenterol; 2024 Jun; 17(3):401-411. PubMed ID: 38528198
[TBL] [Abstract][Full Text] [Related]
10. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
[TBL] [Abstract][Full Text] [Related]
11. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.
Kelley RK; Meyer T; Rimassa L; Merle P; Park JW; Yau T; Chan SL; Blanc JF; Tam VC; Tran A; Dadduzio V; Markby DW; Kaldate R; Cheng AL; El-Khoueiry AB; Abou-Alfa GK
Clin Cancer Res; 2020 Sep; 26(18):4795-4804. PubMed ID: 32636319
[TBL] [Abstract][Full Text] [Related]
12. Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC.
Toyoda H; Kumada T; Tada T; Sone Y; Kaneoka Y; Maeda A
Liver Cancer; 2015 Mar; 4(2):126-36. PubMed ID: 26020034
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and Prognostic Ability of Contrast-Enhanced Unltrasound and Biomarkers in Hepatocellular Carcinoma Subtypes.
Xu W; Huang B; Zhang R; Zhong X; Zhou W; Zhuang S; Xie X; Fang J; Xu M
Ultrasound Med Biol; 2024 Apr; 50(4):617-626. PubMed ID: 38281888
[TBL] [Abstract][Full Text] [Related]
14. The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma.
Olbrich A; Niemeyer J; Seiffert H; Ebel S; Gros O; Lordick F; Forstmeyer D; Seehofer D; Rademacher S; Denecke T; Matz-Soja M; Berg T; van Bömmel F
J Cancer Res Clin Oncol; 2024 Feb; 150(2):81. PubMed ID: 38319485
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral plasmacytoid dendritic cells as a poor prognostic factor for hepatocellular carcinoma following curative resection.
Zhou ZJ; Xin HY; Li J; Hu ZQ; Luo CB; Zhou SL
Cancer Immunol Immunother; 2019 Aug; 68(8):1223-1233. PubMed ID: 31201473
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection.
Ma XL; Gao XH; Gong ZJ; Wu J; Tian L; Zhang CY; Zhou Y; Sun YF; Hu B; Qiu SJ; Zhou J; Fan J; Guo W; Yang XR
Oncotarget; 2016 Oct; 7(43):70654-70668. PubMed ID: 27683106
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study.
El-Fattah MA; Aboelmagd M; Elhamouly M
United European Gastroenterol J; 2017 Mar; 5(2):227-235. PubMed ID: 28344790
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors.
Yang LM; Wang HJ; Li SL; Gan GH; Deng WW; Chang YS; Zhang LF
World J Gastroenterol; 2024 Mar; 30(11):1533-1544. PubMed ID: 38617449
[TBL] [Abstract][Full Text] [Related]
19. The Utility of Serum Alpha-fetoprotein for Monitoring for Relapse of Alpha-fetoprotein-Positive Hepatoblastoma.
Davini M; Hastings C; Feusner J
J Pediatr Hematol Oncol; 2024 May; 46(4):206-210. PubMed ID: 38551915
[TBL] [Abstract][Full Text] [Related]
20. Aberrant phosphorylation of human LRH1 at serine 510 is predictable of hepatocellular carcinoma recurrence.
Nishimagi A; Kobayashi M; Sugimoto K; Kofunato Y; Sato N; Haga J; Ishigame T; Kimura T; Kenjo A; Kobayashi Y; Hashimoto Y; Marubashi S; Chiba H
Clin Exp Med; 2023 Dec; 23(8):4985-4995. PubMed ID: 37285077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
